In addition, the severity of nephrotic syndrome was greater in the obinutuzumab or ofatumumab group than in the rituximab group (serum albumin 25.2 vs. 30.0 g/l and urine protein-to-creatinine ratio 5.9 vs. 5.7 g/g), although this was not statistically significant. The gene discussed is ALB; the disease is nephrotic syndrome.